Evidence map›Paper›PMID 30760858›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors.

Jerzy Lasota, Artur Kowalik, Anna Felisiak-Golabek, Sebastian Zięba, Piotr Waloszczyk, Marek Masiuk, Jaroslaw Wejman, Justyna Szumilo, Markku Miettinen

Open access · bronzeAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Primary melanoma of the gastrointestinal tract.World journal of gastroenterology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Primary malignant melanoma of the oesophagus.United European gastroenterology journal · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Histopathological landscape of rare oesophageal neoplasms.World journal of gastroenterology · 2020
    Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Jerzy LasotaLaboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, USA. jerzy.lasota@nih.gov.
Artur KowalikDepartment of Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland.ORCID http://orcid.org/0000-0002-3718-999X
Anna Felisiak-GolabekLaboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
Sebastian ZiębaDepartment of Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland.
Piotr WaloszczykZdunomed Independent Laboratory of Pathology, Szczecin, Poland.
Marek MasiukDepartment of Pathology, Pomeranian Medical University, Szczecin, Poland.
Jaroslaw WejmanCenter for Medical Postgraduate Education, Warszawa, Poland.
Justyna SzumiloDepartment of Clinical Pathomorphology, Medical University of Lublin, Lublin, Poland.
Markku MiettinenLaboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
National Cancer Institute · USHoly Cross University · PLMedical University of Lublin · PLPomeranian Medical University · PLPostgraduate School of Molecular Medicine · PL

Funding

Immunohistochemical and genomic analysis of tumorsZIABC011427 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MIETTINEN, MARKKU · 2012 to 2025
$24.0M
Intramural NIH HHS ZIA BC011427
6 · The paper itself

Abstract

Primary malignant melanoma of esophagus is very rare, and its clinicopathologic and genetic features have not been extensively investigated. In this study, 20 tumors from 14 male and 6 female patients (40-79 years old) were evaluated. Dysphagia, chest pain, and weight loss were frequent symptoms. Thirteen melanomas, including two with multiple lesions, involved the distal third of esophagus. The median tumor diameter was 6 cm. Epithelioid morphology, moderate atypia, and pigmentation were typical findings. None of the patients had melanoma elsewhere, and all tumors exhibited a junctional peri-epithelial component consistent with a primary lesion. The median mitotic activity was 11 per 10 high-power fields (range, 0-31). Nine patients died of tumor within 4-22 months, however, two showed long-term (96 and 104 months) survival. In 15 cases, tissue for further immunohistochemical and molecular studies were available. BRAF, KIT, and NRAS mutation status was assessed by Sanger sequencing in all 15 tumors. The next-generation sequencing of 50 or 409 genes was performed in five and three cases, respectively. IGF1R expression indicating activation of the IGF axis was seen in 82% (9/11) of tumors. However, no BRAF mutations were identified. In 33% (5/15) of tumors, NRAS mutations were detected. KIT expression was seen in 50% (7/14) of melanomas including single KIT mutant. Two of three tumors evaluated with 409 genes panel revealed multiple driver mutations indicating sub-clonal expansion, whereas a single mutation (TSC1 p.H371Q) was the sole change in the third case. SF3B1 p.K666T and p.R625C mutations were detected in two cases. However, no co-occurrence of SF3B1 and GNAQ or GNA11 mutations, seen in uveal melanoma, was detected. FBXW7 p.R465C and p.R479G mutations, linked to cancer progression, were found in two of eight tumors. In summary, esophageal melanoma mutation profile indicates complexity of molecular mechanisms underlying its pathogenesis.

Indexed as

AdultAgedBiomarkers, TumorDNA Mutational AnalysisEsophageal NeoplasmsFemaleGTP PhosphohydrolasesHigh-Throughput Nucleotide SequencingHumansMaleMelanomaMembrane ProteinsMiddle AgedProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kitBiomarkers, TumorBRAF protein, humanGTP PhosphohydrolasesKIT protein, humanMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kit

Identifiers

PMID30760858
PMCPMC8210848
OpenAlexW2912498836

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.